PF-Atlas › Clinical Trials › NCT05095246

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

KB407 · Phase 1

Registry ID

NCT05095246

Phase

Phase 1

Status

Withdrawn

Drug / intervention

KB407 (Nebulization)

Sponsor

Krystal Biotech, Inc.

Start

2022-03-08

About this trial

KB407 is evaluated in NCT05095246, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Krystal Biotech, Inc.. Current status: Withdrawn.

View NCT05095246 on ClinicalTrials.gov →

Explore related

All KB407 trials All IPF trials

Related trials

KB407 — NCT05504837

Medical disclaimer. This page summarizes public trial data for NCT05095246 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.